Ameliorative effects of Xue-Fu-Zhu-Yu decoction, Tian-Ma-Gou-Teng-Yin and Wen-Dan decoction on myocardial fibrosis in a hypertensive rat mode

详细信息    查看全文

• 作者：Guohua Zhang ; Guang Yang ; Yan Deng…
• 关键词：Xue ; Fu ; Zhu ; Yu decoction ; Tian ; Ma ; Gou ; Teng ; Yin ; Wen ; Dan decoction ; Hypertension ; Myocardial fibrosis ; SHR ; TGF ; β1
• 刊名：BMC Complementary and Alternative Medicine
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：668 KB
• 参考文献：1.Ozawa K, Funabashi N, Kataoka A, Tanabe N, Yanagawa N, Tatsumi K, et al. Myocardial fibrosis in the right ventricle detected on ECG gated 320 slice CT showed a short term poor prognosis in subjects with pulmonary hypertension. Int J Cardiol. 2013;168(1):584–6.CrossRef PubMed
  2.Medvedev NV, Gorshukova NK. Pathogenetic significance of interstitial fibrosis in development myocardial dysfunction and chronic heart failure in elderly patients with arterial hypertension. Adv Gerontol. 2013;26(1):130–6.PubMed
  3.Sowers JR. Hypertension myocardial fibrosis. J Clin Hypertens. 2007;9(7):558–9.CrossRef
  4.Xu X, Tan X, Tampe B, Nyamsuren G, Liu X, Maier LS, et al. Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc Res. 2015;105(3):279–91.CrossRef PubMed
  5.Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology. 2006;118(1):10–24.PubMedCentral CrossRef PubMed
  6.Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res. 2007;74(2):207–12.CrossRef PubMed
  7.Yoshimatsu Y, Watabe T. Roles of TGF-beta signals in endothelial-mesenchymal transition during cardiac fibrosis. Int J Inflamm. 2011;2011:724080.CrossRef
  8.Lee JJ, Hsu WH, Yen TL, Chang NC, Luo YJ, Hsiao G, et al. Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats. J Ethnopharmacol. 2011;134(3):824–30.CrossRef PubMed
  9.Ziegelhoffer-Mihalovicova B, Arnold N, Marx G, Tannapfel A, Zimmer HG, Rassler B. Effects of salt loading and various therapies on cardiac hypertrophy and fibrosis in young spontaneously hypertensive rats. Life Sci. 2006;79(9):838–46.CrossRef PubMed
  10.Bing OH, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol. 1995;27(1):383–96.CrossRef PubMed
  11.Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 1995;91(1):161–70.CrossRef PubMed
  12.Engelmann GL, Vitullo JC, Gerrity RG. Morphometric analysis of cardiac hypertrophy during development, maturation, and senescence in spontaneously hypertensive rats. Circ Res. 1987;60(4):487–94.CrossRef PubMed
  13.Cutilletta AF, Erinoff L, Heller A, Low J, Oparil S. Development of left ventricular hypertrophy in young spontaneously hypertensive rats after peripheral sympathectomy. Circ Res. 1977;40(4):428–34.CrossRef PubMed
  14.Sen S, Bumpus FM. Collagen synthesis in development and reversal of cardiac hypertrophy in spontaneously hypertensive rats. Am J Cardiol. 1979;44(5):954–8.CrossRef PubMed
  15.Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res. 1974;35(5):775–81.CrossRef PubMed
  16.Xue M, Chen KJ, Ma XJ, Liu JG, Jiang YR, Miao Y, et al. Effects of Xuefu Zhuyu Oral Liquid on hemorheology in patients with blood-stasis syndrome due to coronary disease and their relationship with human platelet antigen-3 polymorphism. Zhong Xi Yi Jie He Xue Bao. 2008;6(11):1129–35.CrossRef PubMed
  17.Li Y, Chen K, Shi Z. Effect of xuefu zhuyu pill on blood stasis syndrome and risk factor of atherosclerosis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1998;18(2):71–3.PubMed
  18.Shiyun HU, Shaoxiang X, Licheng Z. Effect of tianma gouteng decoction on myocardial fibrosis in renovascular hypertensive rats. Traditional Chinese drug research & clinical pharmacology. 2006;17(2):97–9.
  19.Zhang TX, Wang YF, Ciriello J. The herbal medicine tian ma gou teng yen alters the development of high blood pressure in the spontaneously hypertensive rat. Am J Chin Med. 1989;17(3–4):211–9.CrossRef PubMed
  20.Zhong-qiang JI, Wen-hui WU, Wen-yan JI. Mechanism study of the impacts on myocardial fibrosis treated with modified xuefu zhuyu decoction in the rats with hypertension. World journal of integrated of traditional and western medicine. 2011;06(5):385–8.
  21.Gao D, Jiao YH, Wu YM. Experimental study of Xuefu Zhuyu Decoction induced participation of endothelial progenitor cells in the angiogenesis of the ischemic region. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012;32(2):224–8.PubMed
  22.Guohua Z. Effect of Wendan decoction on lipid metabolism in hyperlipidemic adult rats. Hebei journal of traditional Chinese medicine. 2007;7(5):28–9.
  23.Wang L, Song Y, Li F, Liu Y, Ma J, Mao M, et al. Effects of Wen Dan Tang on insomnia-related anxiety and levels of the brain-gut peptide Ghrelin. Neural regeneration research. 2014;9(2):205–12.PubMedCentral CrossRef PubMed
  24.Fritz M, Rinaldi G. Blood pressure measurement with the tail-cuff method in Wistar and spontaneously hypertensive rats: influence of adrenergic- and nitric oxide-mediated vasomotion. J Pharmacol Toxicol Methods. 2008;58(3):215–21.CrossRef PubMed
  25.Jia H, Chen XL, Chen C, Hu YY, Yun XJ. Baicalin prevents the up-regulation of connective tissue growth factor in fibrotic lungs of rats. Sheng Li Xue Bao. 2010;62(6):535–40.PubMed
  26.Zhai Y, Gao X, Wu Q, Peng L, Lin J, Zuo Z. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol. 2008;587(1–3):196–203.CrossRef PubMed
  27.Akashiba A, Ono H, Ono Y, Ishimitsu T, Matsuoka H. Valsartan improves L-NAME-exacerbated cardiac fibrosis with TGF-ss inhibition and apoptosis induction in spontaneously hypertensive rats. J Cardiol. 2008;52(3):239–46.CrossRef PubMed
  28.Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32(5):1454–9.CrossRef PubMed
  29.Assayag P, Carre F, Chevalier B, Delcayre C, Mansier P, Swynghedauw B. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res. 1997;34(3):439–44.CrossRef PubMed
  30.Fortuno MA, Ravassa S, Fortuno A, Zalba G, Diez J. Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension. 2001;38(6):1406–12.CrossRef PubMed
  31.Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens. 2007;9(7):546–50.CrossRef
  32.Caglayan E, Stauber B, Collins AR, Lyon CJ, Yin F, Liu J, et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes. 2008;57(9):2470–9.PubMedCentral CrossRef PubMed
  33.Rossi MA, Peres LC. Effect of captopril on the prevention and regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy. Am Heart J. 1992;124(3):700–9.CrossRef PubMed
  34.Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation. 2005;111(19):2509–17.CrossRef PubMed
  35.Simko F. Physiologic and pathologic myocardial hypertrophy--physiologic and pathologic regression of hypertrophy? Med Hypotheses. 2002;58(1):11–4.CrossRef PubMed
  36.Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569–82.CrossRef PubMed
  37.Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6:597–641.CrossRef PubMed
  38.Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51(4):600–6.PubMedCentral CrossRef PubMed
  39.Zhishan D, Chengxian G, Ruirui J, Xingde W. Effects of XueFuZhuYu decoction on collagen synthesis and proliferation of cardiac fibroblasts. Journal of Chinese Medicinal Materials. 2002;07:481–3.
  40.\Miya Y, Jingping O, Yanfang Z: Effects of Sodiumferulate on the Proliferation of Cardiac Fibroblasts. Medical Journal of Wuhan University 2006(02):148-151+278.
  41.Hailing R, Shisen J, Dujiang X, Chunhui W, Tao H: Effect of Ligustrazine on myocardial fibrosis in rats with pressure overload. Mod Rehab. 2003;(12):1748-1749+1875.
  42.Fa L, Yuan W, Xinzhong Y, Fanggui L, Jian H, Ruifen C. The antihypertensive effect of carthamin yellow and the impact on renin angiotensin in hypertensive rats. Acta Pharmaceutica Sinica. 1992;10:785–7.
  43.Guangsheng Y, Mingui T, Wangchun R, Jiahe H, Zhabang Z, Yongzhen H, et al. Peach kernel research for the treatment of schistosomiasis cirrhosis. J Tradit Chin Med. 1986;06:24–5.
  44.Chunfu W. Research on the pharmacological of peony and its chemical constituents. Traditional Chinese Medicine Bulletin. 1985;06:45–7.
  
• 作者单位：Guohua Zhang (1)
  Guang Yang (2)
  Yan Deng (1)
  Xiangling Zhao (2)
  Yingbao Yang (2)
  Jinjun Rao (2)
  Wenya Wang (2)
  Xin Liu (1)
  Jian He (2)
  Lin Lv (2)
  
  1. School of Traditional Chinese Medicine, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, P. R. China
  2. School of Pharmaceutical Sciences, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, P. R. China
  
• 刊物主题：Complementary & Alternative Medicine; Internal Medicine; Chiropractic Medicine;
• 出版者：BioMed Central
• ISSN：1472-6882

文摘

Background Xue-Fu-Zhu-Yu decoction (XFZYD), Tian-Ma-Gou-Teng-Yin (TMGTY) and Wen-Dan decoction (WDD) are Chinese herbal formulas used to treat hypertension and cardiovascular diseases in traditional Chinese medicine (TCM). The goal of our study is to determine if XFZYD, TMGTY or WDD treatment ameliorated myocardial fibrosis in spontaneously hypertensive rats (SHRs) and to identify the mechanisms underlying any beneficial effects observed during the courses of the investigation.